MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain

Neurotoxicity Research
Hanane KadarRita Raisman-Vozari

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting ~1% of the population older than 60 years. The administration of the proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice is one of the most widely used approach to elucidate the mechanisms of cell death involved in PD. Its toxicity is attributed to its active metabolite 1-methyl-4-phenylpyridinium (MPP(+)). However, the magnitude of the PD-like neurodegeneration induced by MPTP depends on many variables, including the route of administration. Different groups, including us, demonstrated that intranasal (i.n.) administration of MPTP constitutes a new route of toxin delivery to the brain that mimics environmental exposure to neurotoxins. In particular, our previous data showed that mice submitted to acute i.n. MPTP administration displayed a significant decrease of striatal dopamine (DA) and a loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. However, little is known about the timing and the anatomical distribution of MPP(+) after i.n. MPTP administration in mice. In the present study, C57BL/6J mice received one dose of i.n. MPTP (1 mg/nostril) and were sacrificed at two different times after the ad...Continue Reading

References

Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R D BroadwellM Salcman
Nov 13, 1984·European Journal of Pharmacology·J A Javitch, S H Snyder
May 13, 1983·Science·G Kolata
Apr 30, 1984·Biochemical and Biophysical Research Communications·K ChibaN Castagnoli
Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·K J Buck, S G Amara
Sep 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·V Jackson-LewisS Przedborski
Jun 1, 1996·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·F VagliniG U Corsini
Sep 1, 1996·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·F FornaiG U Corsini
Nov 6, 1998·Japanese Journal of Pharmacology·Y KitamuraT Taniguchi
Apr 4, 2000·Nature·M B Feany, W W Bender
Jul 29, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·L Illum
Jul 27, 2001·Current Opinion in Neurology·M VilaS Przedborski
May 29, 2003·Neurology·Paul MerkusFrans W H M Merkus
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Jun 29, 2005·Biochimica Et Biophysica Acta·Jean-Luc Guerquin-KernAlain Croisy
Oct 28, 2006·The European Journal of Neuroscience·Ana I RojoAntonio Cuadrado
May 2, 2007·Mass Spectrometry Reviews·Liam A McDonnell, Ron M A Heeren
Jun 2, 2007·International Journal of Mass Spectrometry·Jeremy L NorrisRichard M Caprioli
Apr 8, 2009·Neuroreport·Nikolay M FilipovShannon C Sistrunk
Jun 27, 2009·Mass Spectrometry Reviews·J Sabine BeckerJ Susanne Becker
Jul 28, 2009·Neurobiology of Disease·Farida BenabdellahSabine De La Porte
Sep 18, 2009·Rapid Communications in Mass Spectrometry : RCM·Yuki Sugiura, Mitsutoshi Setou

❮ Previous
Next ❯

Citations

Oct 22, 2014·Nature Communications·Marion SzelechowskiDaniel Gonzalez-Dunia
Feb 27, 2016·Bioanalysis·Yutaka SugiharaÁkos Végvári
Jun 13, 2015·Assay and Drug Development Technologies·Adeola ShoboThavendran Govender
Jan 30, 2015·Neurotoxicity Research·Juan Segura-Aguilar, Richard M Kostrzewa
Aug 27, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nuramatjan AblatXiaoping Pu
Apr 8, 2017·Journal of Applied Physiology·Sofia D VianaFrederico C Pereira
Sep 2, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Sphamandla NtshangaseSooraj Baijnath
Apr 24, 2020·Frontiers in Pharmacology·Elena Paredes-RodriguezCristina Miguelez
May 18, 2016·Proteomics. Clinical Applications·Rémi LonguespéeEdwin De Pauw
Dec 10, 2016·Archives of Toxicology·Oskar Karlsson, Jörg Hanrieder
Jan 4, 2018·Analytical Chemistry·Sebastiaan Van NuffelAlain Brunelle
Nov 24, 2021·Microscopy and Microanalysis : the Official Journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada·Manale NounImane Abbas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.